VIENNA, Va., Feb. 14 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION
(Amex: CVM) reports financial results for the first quarter fiscal year
2008, ending December 31, 2007.
-- Net loss for the three months ending December 31, 2007 was
approximately $1.84 million compared with an operating loss of
approximately $1.1 million during the quarter ending December 31,
-- The net loss per common share was at $0.02 during the quarter ending
December 31, 2007 compared with the net loss per common share of $0.01
for the quarter ending December 31, 2006.
-- During the three-month period ended December 31, 2007, research and
development expenses doubled compared to the three-month period ended
December 31, 2006. This is due to the increase in work for preparation
of the Phase III clinical study.
About CEL-SCI's Phase III Cancer Drug Multikine:
In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. CEL-SCI is currently building a manufacturing facility for Multikine close to Baltimore, MD. Upon completion of the facility in the 3rd quarter of 2008, CEL-SCI will commence the Phase III clinical trial. Multikine appears to be the first non-toxic cancer drug.
Multikine, a patented defined mixture of naturally der
|SOURCE CEL-SCI Corporation|
Copyright©2008 PR Newswire.
All rights reserved